A Pragmatic, Randomised, Multicentre Trial Comparing 4-Weekly Vs. 12-Weekly Administration of Bone-Targeted Agents (denosumab, Zoledronate or Pamidronate) in Patients with Bone Metastases.
Annals of Oncology（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要